Holen Sie sich die Stockscreener-App
19.41
0.64%
-0.2237
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Nuvectis Pharma Price Target Raised to $33.00/Share From $20.00 by Roth Capital - Moomoo
An Insider Of Nuvectis Pharma Picks Up 1.5% More Stock - 富途牛牛
What makes Nuvectis Pharma, Inc. (NVCT) a strong momentum stock: Buy now? - MSN
Nuvectis Pharma announces public share offering to support drug programs - MSN
Nuvectis Pharma Announces Major Public Equity Offering - The Globe and Mail
Insider Buying: Ron Bentsur Acquires Additional Shares of Nuvect - GuruFocus
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock By Investing.com - Investing.com South Africa
Nuvectis Pharma CEO Ron Bentsur buys $250,000 in company stock - Investing.com
[Form 4] Nuvectis Pharma, Inc. Insider Trading Activity - Stock Titan
Form 4 Nuvectis Pharma Inc For: 1 July By Investing.com - Investing.com India
Nuvectis Pharma 10% owner Mosseri buys $916k in shares - Investing.com UK
Nuvectis Pharma 10% owner Mosseri buys $916k in shares By Investing.com - Investing.com Australia
Nuvectis Pharma (NVCT) CEO Ron Bentsur buys $250,000 in shares - Stock Titan
Nuvectis: 'Hold' On NXP800 Removal And Newly Licensed Candidates (NASDAQ:NVCT) - Seeking Alpha
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Nuvectis Raises $100M for Oncology Pivot - AllSci
Form 424B5 Nuvectis Pharma Inc For: 30 June - Investing.com UK
Form 424B5 Nuvectis Pharma Inc For: 30 June By Investing.com - Investing.com Nigeria
Nuvectis Pharma Sets 5M-Share, $20 Offering; ~$93M Net, Cantor Fitzgerald Underwriter - TradingView
Nuvectis Pharma (NASDAQ: NVCT) to raise $100M in stock sale - Stock Titan
Nuvectis Pharma (NVCT) files $100M offering; 5.0M shares at $20.00 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Nuvectis gains two experimental drugs in licensing deal with China's Haisco - MSN
Nuvectis shares continue to rally after $1.46B Haisco deal - BioWorld News
Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT) - Yahoo Finance
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stoc - Benzinga
Nuvectis Pharma stock tumbles 25% on discounted offering By Investing.com - Investing.com Canada
Nuvectis Pharma Prices $100 Million Secondary Stock Offering; Shares Down Pre-Bell - Moomoo
Nuvectis Pharma's $100 Million Offering: Dilution at a Discount Amidst Pipeline Hopes - Kavout | AI
Nuvectis locks in $100M from 5 million-share stock sale - Stock Titan
Nuvectis Pharma Intends to Use Net Proceeds From Offering to Advance Development Programs >NVCT - Moomoo
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Sahm
Nuvectis Pharma prices $100 million public offering at $20/share By Investing.com - Investing.com Australia
Nuvectis Pharma prices $100 million public offering at $20/share - Investing.com
Nuvectis Pharma Prices $100 Million Underwritten Public Offering of Common Stock - Quiver Quantitative
Press Release: Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock - Moomoo
Form 424B5 Nuvectis Pharma Inc For: 29 June - Investing.com UK
Form 424B5 Nuvectis Pharma Inc For: 29 June By Investing.com - Investing.com South Africa
Nuvectis Pharma Announces Proposed Public Offering of Common Stock - Investing News Network
Nuvectis Pharma launches public offering of common stock By Investing.com - Investing.com South Africa
Nuvectis Pharma stock tumbles on public offering launch By Investing.com - Investing.com South Africa
Nuvectis Pharma prices $100 million public offering of common stock - scanx.trade
Nuvectis Pharma Suspends Equity Offering Program Under Agreement - TipRanks
Nuvectis (NASDAQ: NVCT) prelim prospectus; Haisco license, $20M upfront - Stock Titan
Nuvectis Pharma launches public offering of common stock - Investing.com
Nuvectis Pharma Launches Proposed Public Stock Offering - Moomoo
Nuvectis Pharma stock tumbles on public offering launch - Investing.com UK
1.16%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):